Sun, Apr 20, 2014, 3:35 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Dendreon Corp. Message Board

  • traderpro007 traderpro007 Dec 13, 2004 7:22 PM Flag

    diff between ingn and dndn and biom

    diff between ingn and dndn and biom ?

    which one would be good for LONG TERM?

    thanks for the ideas....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • i own ingn, it just finished a huge financing, and early trial data has been coming out. well worth a look.

      • 1 Reply to sirbailey_2000
      • I used to own INGN (significantly). I always had trouble with the way their drug is delivered - they have to inject the drug directly into the tumor - many times because the drug only has limited geography. What happens when you don't find the tumor? Also they have a board member named Kapoor - who although is loaded has a jaded background. Be careful here - and I know they just did their secondary for some interim money but when you think INGN, think delivery. Whenever you think it might be a good investment because of their many announcements (repeaters I might add) think DELIVERY.

    • No contest. Biom has been around forever and has accomplished little so far. It doesn't have much cash and has just had to raise some. The approach they take is to try to immunize cancer patients with super antigens. However, these patients are already, for the most part, immunologically comprised and I don't think standard vaccine procedures, even with a supposed super antigen, are likely to be effective. Neither does the market which places a market cap south of .3 M om biom. Also there is little insider ownership and no insider buying. Ingn I think is even worse. They only have about 20 mil in cash and are likely to need more soon. Also I don't think more p53 is going to cure anyone of anything. Its just another standard gene therapy ploy and IMO is not likely to be terribly effective. Furthermore, its likely that by the time most patients are diagnosed they are going to be beyond the help of tumor supressor genes. Of the 3, dndn has the most novel methodology, likely the least toxic product, and the broadest applicability to a variety of tumors. But that just my opinion.

 
DNDN
2.65-0.04(-1.49%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AsiaInfo-Linkage, Inc.
NasdaqGSWed, Jan 15, 2014 4:00 PM EST